ÂÜÀòÂÒÂ×

Lori Friedman is a prominent figure in the biotechnology industry with extensive experience in scientific leadership. Currently serving as a Board member at NextRNA Therapeutics since September 2023, Lori has held the position of Chief Scientific Officer at ORIC Pharmaceuticals since July 2019. Prior to this, Lori held various senior roles at Genentech from July 2004 to July 2019, including Sr. Director of Translational Oncology and Director of Cancer Signaling and Translational Oncology. Lori's early career includes significant positions at Exelixis from March 1998 to June 2004, where responsibilities encompassed Director of Signal Transduction Research and Oncology Program Leader. Lori's educational background features a PhD in Molecular and Cell Biology from the University of California, Berkeley, and post-doctoral fellowships in Breast Cancer Genetics at Cambridge University and the University of Washington, complemented by a B.S. in Microbiology from the University of Iowa.